Drugs reduce bone cancer damage but clinical guidance remains non-specific

May 15, 2012, Wiley

Bone cancer-related fractures and pain can be reduced by drug treatment, but no one drug is superior, according to a review published in The Cochrane Library. Researchers undertook a systematic review of the current evidence on bisphosphonate drugs, which are used to prevent bone damage in multiple myeloma.

Multiple myeloma is a type of cancer that grows in and on bones, and can cause fractures in long bones and the spine. Severe back pain is a common symptom. Bisphosphonate drugs may help to reduce the occurrence of fractures and bone pain in myeloma patients. They work by inhibiting the activities of called , which are involved in the formation of fractures. Many different bisphosphonate drugs are available, but their relative merits are uncertain.

The researchers analysed data from 20 trials involving a total of 6,692 patients who took bisphosphonate drugs including zoledronate, clodronate, pamidronate, ibandronate and etidronate in addition to their myeloma treatments. reduced the occurrence of fractures and pain. For all types of fractures, the researchers estimated that between 6 and 15 patients would need to be treated to prevent fractures in one patient. For pain, between 5 and 13 patients would need to be treated to reduce pain in one patient.

Four trials made direct comparisons between different drugs. In the remaining trials, the effects of the drugs were compared to those of placebos or no treatment and the researchers made indirect comparisons by interrogating the data from these trials. Head-to-head trials suggested that zoledronate was more effective at reducing fractures compared to etidronate, but taken together with the indirect comparisons, the researchers conclude that no one drug can be regarded as superior.

"Whether zoledronate is superior to any other bisphosphonate drug remains an open question," said lead researcher Ambuj Kumar of the Center for Evidence Based Medicine and Health Outcomes Research at the University of South Florida, in Tampa, Florida. "In light of the inconsistencies we see in the data, it is difficult to recommend any as a preferential treatment for clinical practice."

Based on the findings of the review, adverse effects of bisphosphonate drugs appear to be rare. Osteonecrosis of the jaw (a disease whereby the jaw bone can appear through lesions in the gum which do not heal) is one potential complication that has been gaining attention in recent years, but the authors report that it is no more common in those taking bisphosphonate drugs than in those receiving placebos or no treatment. "We didn't identify any significant adverse effects, but this work does highlight the need for larger head-to-head trials, which are needed to better compare the safety and effectiveness of the different drugs available," said Kumar.

Explore further: Yearly zoledronic acid at lower-than-standard doses increases bone density

More information: Mhaskar R, Redzepovic J, Wheatley K, Clark OAC, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD003188. DOI: 10.1002/14651858.CD003188.pub3

Related Stories

Yearly zoledronic acid at lower-than-standard doses increases bone density

June 6, 2011
A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic ...

Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half

February 8, 2012
There is growing evidence that supports an association between atypical fractures of the femur– a rare break of the thigh bone, typically without trauma – and the use of bisphosphonates, drugs proven to enhance ...

Recommended for you

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.